The thrombin antagonist hirudin fails to inhibit endotoxin-induced leukocyte/endothelial cell interaction and microvascular perfusion failure.
Besides its central role in coagulatory pathways, thrombin is known to be a key mediator of macrophage and granulocyte activation in vitro. During recent years the concept of thrombin inhibition by the specific thrombin inhibitor, hirudin, has been established to treat septic disorders. Since basic mechanisms of sepsis include leukocyte/endothelial cell interaction and deterioration of capillary perfusion, we hypothesized that hirudin modulates leukocyte activation and microvascular injury. Severe endotoxemia was induced in Syrian hamsters by intravenous administration of endotoxin (lipopolysaccharide [LPS], E. coli, 2mg/kg) at 0 h. Hirudin (0.25 mg/kg/h) was substituted intravenously during the 4 h after the induction of endotoxemia (n = 7, hirudin). In control animals (n = 6, control) LPS was given without hirudin substitution. In skinfold chamber preparations leukocyte/endothelial cell interaction and functional capillary density (FCD, measure of capillary perfusion) were analyzed during a 24-h period after LPS injection using intravital fluorescence microscopy. Hirudin effectively normalized thromboplastin time and antithrombin activity when compared to controls (P < 0.05, ANOVA). However, hirudin did not attenuate LPS-induced arteriolar and venular leukocyte adherence, and even tended to increase leukocyte adherence after 24 h (P > 0.05, MANOVA). In parallel, addition of hirudin led to a significant deterioration of FCD over time when compared to controls (hirudin: baseline = 171 +/- 19 cm(-1) versus 16 +/- 9 at 24 h; control: baseline = 150 +/- 20 cm(-1) versus 62 +/- 18 at 24 h; P < 0.05). The fall in FCD in hirudin animals was associated with a significant increase of wet-to-dry weight ratios in lung, kidney, muscle, and small intestine (P < 0.05 versus control, ANOVA). Thus our study does not indicate a protective effect of hirudin on microcirculation during endotoxemia, despite an improvement of coagulatory parameters. This result may at least in part explain the lack of efficacy of hirudin on lethality during endotoxemia and sepsis.
Hoffmann
J N
JN
Department of Surgery, Klinikum Grosshadern, Ludwig-Maximilians University, Munich, Germany.
Vollmar
B
B
Inthorn
D
D
Schildberg
F W
FW
Menger
M D
MD
D000818:Animals; D000991:Antithrombins / Q000494:pharmacology*; D001160:Arterioles / Q000187:drug effects / Q000473:pathology; D006224:Cricetinae; D004487:Edema; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D004731:Endotoxins / Q000633:toxicity*; D004926:Escherichia coli; D006629:Hirudins / Q000494:pharmacology*; D007421:Intestine, Small / Q000473:pathology; D007962:Leukocytes / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D008070:Lipopolysaccharides / Q000633:toxicity*; D008099:Liver / Q000473:pathology; D008168:Lung / Q000473:pathology; D008647:Mesocricetus; D008833:Microcirculation / Q000187:drug effects / Q000473:pathology / Q000502:physiology*; D018482:Muscle, Skeletal / Q000473:pathology; D009929:Organ Size / Q000187:drug effects; D014699:Venules / Q000187:drug effects / Q000473:pathology
D000991:Antithrombins; D004731:Endotoxins; D006629:Hirudins; D008070:Lipopolysaccharides